Company Overview - Zelluna ASA is focused on pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for cancer treatment, aiming to deliver transformative therapies for advanced solid cancers globally [1][3] - The company’s TCR-NK platform is designed to provide a unique mechanism of action with broad cancer detection capabilities, addressing the diversity of tumors and overcoming scaling limitations of current cell therapies [3] Event Announcement - An Investor Science and Strategy Forum will be held on 17 September 2025 in Oslo, featuring a panel discussion and open Q&A session [1][2] - The event will include prominent figures such as Dr. Namir Hassan, CEO of Zelluna, and Prof. Bent Jakobsen, a pioneer in TCR therapy for cancer [1] Event Details - Date and Time: 17 September 2025, from 11:30 to 13:00 CET, with lunch served [2] - Venue: Meeting Room 4, Hotel Continental, Stortingsgata 24/26, Oslo [2] - Registration is required, and spaces are limited, with a confirmation deadline of 15 September 2025 [3]
Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025
Globenewswire·2025-09-10 06:00